Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized withdrawal study of vixotrigine for painful small fiber neuropathy
2017-000991-27Phase 2Unknown
- Sponsor
- Biogen
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vixotrigine in small fiber neuropathy (SFN) (3 arms), sponsored by Biogen. Primary endpoint: Change from baseline in weekly mean average daily pain score. Status: unknown.
02
Drugs
vixotrigine
03
Conditions
small fiber neuropathy (SFN)
Beyond the preview
Go deeper on 2017-000991-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000991-27.